Metenkefalin
- Generic Name
- Metenkefalin
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N5O7S
- CAS Number
- 58569-55-4
- Unique Ingredient Identifier
- 9JEZ9OD3AS
- Background
Metenkefalin is an endogenous opioid and beta-endorphin. It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.
- Indication
Metenkefalin is indicated in Bosnia for the treatment of relapsing-remitting multiple sclerosis.
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
- Conditions
- COVID-19 Infection
- Interventions
- Drug: The standard of care
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Bosnalijek D.D
- Target Recruit Count
- 120
- Registration Number
- NCT04374032
- Locations
- 🇧🇦
University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
🇧🇦Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina
INNO-105 in Patients With Solid Tumors
- Conditions
- Tumors
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-05-14
- Lead Sponsor
- Innovive Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00255333
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.